Genentech Raptiva Script Growth Impacted By Enbrel Psoriasis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The number of "statements of medical necessity" for new Raptiva patients declined by 1,000 during the second quarter. Amgen's Phase IV trial for Enbrel could take more than 4,000 patients out of the psoriasis market.
You may also be interested in...
Amgen Enbrel Clears FDA For Psoriasis Supplemental Indication; Detailing Begins Immediately
The company calls on 3,500 dermatologists for its psoriatic arthritis indication; Amgen hopes to increase promotion to 9,000 dermatolgists.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: